Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma.

Autor: Fayon M; Institut de recherche Saint-Louis, Inserm U976., Martinez-Cingolani C; Institut de recherche Saint-Louis, InsermU976., Abecassis A; Institut de recherche Saint-Louis, Inserm U976., Roders N; Institut de recherche Saint-Louis, Inserm U976., Nelson E; Institut de recherche Saint-Louis, Inserm U976., Choisy C; Institut de recherche Saint-Louis, Inserm U976., Talbot A; Immunology-Haematology department, Hôpital Saint-Louis, AP-HP., Bensussan A; Institut de recherche Saint-Louis, Inserm U976., Fermand JP; Immunology-Haematology department, Hôpital Saint-Louis, AP-HP., Arnulf B; Immunology-Haematology department, Hôpital Saint-Louis, AP-HP., Bories JC; Institut de recherche Saint-Louis, Inserm U976.
Jazyk: angličtina
Zdroj: Haematologica [Haematologica] 2021 Apr 01; Vol. 106 (4), pp. 1193-1197. Date of Electronic Publication: 2021 Apr 01.
DOI: 10.3324/haematol.2019.242453
Databáze: MEDLINE